1. Home
  2. Publications & whitepapers
  3. Development of orphan products and the impact of the EU Paediatric Regulation, TOPRA Vol 9, No.10

Development of orphan products and the impact of the EU Paediatric Regulation, TOPRA Vol 9, No.10

Published on: Oct 15, 2012

 

Development of orphan medicinal products (OMPs) is challenging by nature: knowledge is usually limited; the patient population are small and often frail; and the implementation of the Paediatric Regulation in the EU has added a layer of complexity, especially for OMPs.

Marie Deneux, Séverine Marconi, David Uguen

2012 – Regulatory Rapporteur

Download the full resource now
Fill in the form to download the content
Thank you ! Your file is ready to download. Click here to download